A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

• Upadacitinib (Drug): Oral Tablet
• Tofacitinib (Drug): Oral Tablet
• Baricitinib (Drug): Oral Tablet

Primary outcomes

• Number of Participants With Treatment Emergent Adverse Events (TEAE) [Up to 44 Days]: An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
• Average plasma concentration (Cavg) of Upadacitinib [Up to 44 Days]: Cavg of Upadacitinib
• Average plasma concentration (Cavg) of Tofacitinib [Up to 44 Days]: Cavg of Tofacitinib
• Average plasma concentration (Cavg) of Baricitinib [Up to 44 Days]: Cavg of Baricitinib
• Area under the concentration-time curve over 24 hours (AUC24) of Upadacitinib [Up to 44 Days]: AUC24 of Upadacitinib
• Area under the concentration-time curve over 24 hours (AUC24) of Tofacitinib [Up to 44 Days]: AUC24 of Tofacitinib
• Area under the concentration-time curve over 24 hours (AUC24) of Baricitinib [Up to 44 Days]: AUC24 of Baricitinib
• Maximum Observed Plasma Concentration (Cmax) of Upadacitinib [Up to 44 Days]: Cmax of Upadacitinib
• Maximum Observed Plasma Concentration (Cmax) of Tofacitinib [Up to 44 Days]: Cmax of Tofacitinib
• Maximum Observed Plasma Concentration (Cmax) of Baricitinib [Up to 44 Days]: Cmax of Baricitinib

Sex: All, ages: 18 Years to 65 Years, accepts healthy volunteers

Inclusion Criteria:

* Body Mass Index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* A condition of general good health, based upon the results of a medical history, Physical Exam (PE), vital signs, laboratory profile and a 12-lead Electrocardiogram (ECG).
* A female must not be pregnant, or breastfeeding and is not considering becoming pregnant, cryopreserving her eggs or donating eggs during the study or for approximately 30 days after the last dose of study treatment.

Exclusion Criteria:

* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, two or more prior episodes of herpes zoster, or one or more episodes of disseminated herpes zoster, one or more prior episodes of disseminated herpes simplex (including eczema herpeticum) or any uncontrolled medical illness.
* History of any clinically significant sensitivity or allergy to any medication or food.
* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \[e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.\].
* Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
* History or evidence of active tuberculosis (TB) disease or latent TB infection.
* Participant has prior exposure to upadacitinib, tofacitinib or baricitinib within the past 90 days.
* Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis.
* Participant has used any medications, vitamins and/or herbal supplements within the 2-week period prior to study treatment administration.

• ABBVIE INC., Study director, AbbVie